RG 7800

Drug Profile

RG 7800

Alternative Names: RG 7800; RO6885247; SMN2 gene-targeted therapy - PTC Therapeutics; SMN2-targeted therapeutic for spinal muscular atrophy - PTC Therapeutics/SMA Foundation/Roche

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator PTC Therapeutics
  • Developer Roche
  • Class Small molecules
  • Mechanism of Action Survival of motor neuron 1 protein stimulants; Survival of motor neuron 2 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Spinal muscular atrophy

Most Recent Events

  • 01 Jul 2016 Roche terminates the phase I/II MOONFISH trial in Spinal muscular atrophy (In children, In adolescents, In adults, In infants) in United Kingdom, Italy, Turkey, Switzerland, Canada, France, the Netherlands, Sweden and USA (NCT02240355)
  • 04 Oct 2015 Interim efficacy and adverse events data from a phase-I/II trial in Spinal muscular atrophy released by PTC Therapeutics
  • 19 Nov 2014 Phase-I/II clinical trials in Spinal muscular atrophy (In infants, In children, In adolescents, In adults) in Turkey, Italy and Switzerland (PO) (NCT02240355; EudraCT2014-002246-41)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top